Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. (OLIGORESIST)

Radioterapia estereotáctica Fraccionada más antiandrógeno de Segunda generación Para Pacientes oligometastásicos Con cáncer de próstata Resistente a la castración. Estudio español Fase II, Prospectivo, multicéntrico.

The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant prostate cancer in oligometastasis (≤5).

Hence, the investigators evaluate the results of the combination of two widely used treatments in prostate cancer: SBRT plus the 'standard of care' for patients with mCRPC, second-generation antiandrogens (abiraterone and enzalutamide).

Primary objective: Determine the PRFS measured from the time of initiation of second-generation antiandrogen to the time of radiological progression by choline PET/CT or 68Ga-PSMA PET/CT, in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.

Secondary objectives:

  • Overall survival (time from initiation of second-generation antiandrogen to exitus) in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.
  • Quality of life of these patients using the European Organization for Research and Treatment of Cancer (EORTC) quality of life scale, EORTC QLQ-C30, validated for oncology patients.
  • Acute and chronic toxicity according to the "Common Terminology Criteria for Adverse Events" (CTCAEv5.0) scale.

This is a phase II, multicenter, prospective, single group study in patients with castrate-resistant prostate cancer (CRPC).

Patients will be recruited at the participant sites, after study approval and hospital authorization.

51 patients will be included in the study. Eligible patients will require:

  • Choline PET/CT or 68Ga-PSMA PET/CT, dated no more than 8 weeks prior to inclusion.
  • Clinical history, physical examination and functional evaluation scale (ECOG).
  • Geriatric assessment scale for patients > 75 years (modified G8 scale)
  • Toxicity scale assessment (CTCAEv5.0)
  • Baseline quality of life questionnaire (EORTC QLQ-C30) (47)
  • Blood tests with complete blood count, coagulation, liver function, renal function, ions, alkaline phosphatase, PSA and total and free testosterone, dated no more than 4 weeks prior inclusion.
  • Inclusion/exclusion criteria assessment
  • Second generation antiandrogen prescription, chosen by the responsible physician according to clinical practice, in each case.

Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus). SBRT will be performed at least 2 weeks after initiating treatment with second generation antiandrogen, without exceeding 8 weeks from the start of treatment, and follow-up will continue up to a maximum of 36 months after completion of SBRT and/or exitus.

Recruitment time is estimated at 36 months and a total follow-up time of 36 months. The total duration of the trial is therefore expected to be 6 years, to allow complete follow-up of the last patients included.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

51

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Aragon
      • Zaragoza, Aragon, Spanien, 50009
        • Aktiv, inte rekryterande
        • Hospital Universitario Miguel Servet
    • Barcelona
      • Barcelona, Barcelona, Spanien, 08036
        • Rekrytering
        • Hospital Clinic de Barcelona
        • Kontakt:
        • Huvudutredare:
          • Joel Mases i Rosinés, MD
        • Underutredare:
          • Elías Gomís, MD
        • Underutredare:
          • Sara Moreno, MD
        • Underutredare:
          • Gerard Meca, MD
      • L'Hospitalet de Llobregat, Barcelona, Spanien, 08908
        • Rekrytering
        • Instituto Catalán de Oncología Hospitalet
        • Kontakt:
        • Huvudutredare:
          • Ana María Boladeras Inglada, MD
    • Basque Country
      • Bilbao, Basque Country, Spanien, 48013
        • Aktiv, inte rekryterande
        • Hospital Universitario Basurto
    • Castille and León
      • Salamanca, Castille and León, Spanien, 37007
        • Aktiv, inte rekryterande
        • Hospital Universitario De Salamanca
      • Valladolid, Castille and León, Spanien, 47003
        • Rekrytering
        • Hospital Clínico Universitario de Valladolid
        • Kontakt:
        • Huvudutredare:
          • Patricia Diezhandino Garcia, MD
    • Catalonia
      • Barcelona, Catalonia, Spanien, 08041
        • Rekrytering
        • Hospital de La Santa Creu i Sant Pau
        • Kontakt:
        • Kontakt:
          • Saudy Peláez Bonilla, Study coordinator
          • Telefonnummer: 776 +34 935537760
          • E-post: SPelaez@santpau.cat
        • Underutredare:
          • Arantxa Mera Errasti, MD
        • Huvudutredare:
          • Gemma Sancho Pardo, MD
        • Underutredare:
          • Laura Montezuma Niño, MD
        • Underutredare:
          • Ana Maria Soto Cambres, MD
      • Terrassa, Catalonia, Spanien, 08227
        • Aktiv, inte rekryterande
        • Consorci Sanitari de Terrassa
    • Galicia
      • Santiago de Compostela, Galicia, Spanien, 15706
        • Aktiv, inte rekryterande
        • Complexo Hospitalario Universitario De Santiago
    • Madrid
      • Madrid, Madrid, Spanien, 28040
        • Rekrytering
        • Hospital Clinico San Carlos
        • Kontakt:
        • Huvudutredare:
          • Noelia Sanmamed Salgado, MD
        • Underutredare:
          • Manuel Gonzalo Vázquez Masedo, MD
        • Underutredare:
          • Miren Gaztañaga Boronat, MD
        • Underutredare:
          • Maria Nieves Cabrera Martin, MD
        • Underutredare:
          • Natalia Vidal Cassinello, MD
        • Underutredare:
          • Anxela Doval Gonzalez, MD
        • Underutredare:
          • Javier Puente Vazquez, MD
        • Underutredare:
          • Ignacio Moreno, MD
      • Madrid, Madrid, Spanien, 28034
        • Aktiv, inte rekryterande
        • Hospital Ramon y Cajal
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Rekrytering
        • Hospital Universitario de Navarra (HUN)
        • Huvudutredare:
          • Marta Barrado Los Arcos, MD
        • Kontakt:
        • Underutredare:
          • Amaya Sola Galarza, MD
        • Underutredare:
          • Elena Villafranca Iturre, MD
        • Underutredare:
          • Ignacio Visus Fernandez de Manzanos, MD
        • Underutredare:
          • Nuria Bultó Boque, MD
        • Underutredare:
          • Xabier Gurutzeaga Peleato, MD
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spanien, 33011
        • Aktiv, inte rekryterande
        • Hospital Universitario Central de Asturias
    • Valencia
      • Valencia, Valencia, Spanien, 46026
        • Aktiv, inte rekryterande
        • Hospital Universitario y Politécnico de La Fe
    • Vizcaya
      • Barakaldo, Vizcaya, Spanien, 48903
        • Aktiv, inte rekryterande
        • Hospital De Cruces

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Patients with histologically prostate adenocarcinoma, confirmed with a biopsy.
  • Testosterone in biochemical castration ranges (testosterone <50 ng/ml or 1.7 nmol/L) and documented progression: biochemical according to Phoenix criteria or distant by radiological confirmation (PSMA PET/CT or Choline PET/CT)
  • Biochemistry progression confirmed according to Phoenix criteria, with testosterone in castration levels (testosterone <50 ng/ml or 1.7 nmol/L).
  • Radiological confirmation (with choline-PET/CT or 68Ga-PSMA-PET/CT) of ≤5 node or bone metastasis, non-visceral, eligible to receive SBRT treatment (< 3 cm major diameter in bone metastases, < 5 cm in lymph node metastases). In the case of very close metastases, a limit of up to 5 treatment fields with SBRT is allowed, instead of 5 metastases.
  • Patients candidate to receive treatment with abiraterone or enzalutamide as per clinical routine, and treatment selection and prescription assigned by responsible physician before the inclusion in the study. or or who has started treatment no more than 14 days prior to signing, as first-line treatment after a diagnosis of oligoresistance.
  • Patients must provide written informed consent.
  • Life expectancy > 3 months.

Exclusion Criteria:

  • Patients with prostate carcinoma with histology other than adenocarcinoma.
  • No previous biopsy.
  • > 5 metastasis, not approachables in 5 treatment fields
  • Patients with visceral metastasis and or metastasis non elegible to receive SBRT.
  • Patients with Testosterone above castration levels
  • Patients with prior treatment with docetaxel as first-line CRPC treatment (previous docetaxel treatment is permitted when administered as hormone-sensitive metastatic prostate cancer treatment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Second generation antiandrogen plus SBRT
Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus). SBRT will be performed at least 2 weeks after initiating treatment with second generation antiandrogen, without exceeding 8 weeks from the start of treatment, and follow-up will continue up to a maximum of 36 months after completion of SBRT and/or exitus
Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus)
Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus)
Andra namn:
  • abirateronacetat
SBRT will be performed at least 2 weeks after initiating treatment with second generation antiandrogen, without exceeding 8 weeks from the start of treatment, and follow-up will continue up to a maximum of 36 months after completion of SBRT and/or exitus

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Determine the PRFS
Tidsram: From the start of the study (the day it begins) or up to 14 days before the start of the study (corresponding to the start of treatment with second-generation antiandrogens) until the time of radiological progression during follow-up, it can be up to 36.
Determine the PRFS measured from the time of initiation of second-generation antiandrogen to the time of radiological progression by choline PET/CT or 68Ga-PSMA PET/CT, in patients with mCRPC treated with the combination of second-generation antiandrogen
From the start of the study (the day it begins) or up to 14 days before the start of the study (corresponding to the start of treatment with second-generation antiandrogens) until the time of radiological progression during follow-up, it can be up to 36.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall survival
Tidsram: From the start of second-generation antiandrogen therapy (at baseline or up to 14 days prior) to the date of death from any cause, assessed up to 36 months.
Overall survival (time from initiation of second-generation antiandrogen to exitus) in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.
From the start of second-generation antiandrogen therapy (at baseline or up to 14 days prior) to the date of death from any cause, assessed up to 36 months.
Quality of life by EORTC scale
Tidsram: from recruitment to the end of patient follow-up (up to 36 months)

QoL using the European Organization for Research and Treatment of Cancer (EORTC) quality of life scale, EORTC QLQ-C30, validated for oncology patients.

The scale converts all scores to a standardized range from 0 (minimum) to 100 (maximum). A high score indicates a better outcome (high quality of life and good health).

from recruitment to the end of patient follow-up (up to 36 months)
Acute and chronic toxicity
Tidsram: from recruitment to the end of patient follow-up (up to 36 months)
Acute and chronic toxicity according to the "Common Terminology Criteria for Adverse Events" (CTCAEv5.0) scale
from recruitment to the end of patient follow-up (up to 36 months)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Marta Barrado Los Arcos, MD, Hospital of Navarra

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

16 maj 2024

Primärt slutförande (Beräknad)

16 maj 2030

Avslutad studie (Beräknad)

16 maj 2030

Studieregistreringsdatum

Först inskickad

13 juli 2026

Först inskickad som uppfyllde QC-kriterierna

16 juli 2026

Första postat (Faktisk)

21 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera